Filed under: Investing
NYSE Euronext Announces Trading Volumes for August 2013
Global Derivatives ADV Up Year-over-Year but Down Sequentially, Ex Bclear
European Cash Equities ADV Up Year-over-Year but Down Sequentially
U.S. Cash Equities ADV Down Year-over-Year and Sequentially
NEW YORK--(BUSINESS WIRE)-- NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for August 20131. Global derivatives average daily volume ("ADV") of 5.8 million contracts, excluding Bclear, in August 2013 increased 8.6% compared to August 2012, but decreased 8.9% from July 2013. U.S. equity options volumes increased 8.4% compared to August 2012, but decreased 6.0% sequentially. ADV in European cash equities increased 17.9% compared to August 2012, but decreased 7.8% compared to July 2013. U.S. cash equities decreased year-over-year and month-over-month.
- NYSE Euronext global derivatives ADV in August 2013 of 5.8 million contracts, excluding Bclear, increased 8.6% from August 2012, but decreased 8.9% from July 2013 levels.
- NYSE Euronext European derivatives products ADV in August 2013 of 2.4 million contracts, excluding Bclear, increased 10.7% compared to August 2012, but decreased 12.5% from July 2013 levels. Including Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives ADV decreased 12.5% compared to August 2012, and decreased 15.6% from July 2013.
- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of 3.3 million contracts in August 2013 increased 8.4% compared to August 2012 levels, but decreased 6.0% from July 2013 levels. NYSE Euronext's U.S. options exchanges accounted for 25.3% of total U.S. consolidated equity options trading in August 2013, up from 24.8% in August 2012, but down from 26.6% in July 2013.
- NYSE Liffe U.S. ADV of approximately 31,400 contracts decreased from 63,200 contracts in August 2012 and decreased from 35,000 contracts in July 2013.
- NYSE Euronext European cash products ADV of 1.3 million transactions in August 2013 increased 17.9% compared to August 2012 but, decreased 7.8% compared to July 2013.
- NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.3 billion shares in August 2013 decreased 7.5% compared to August 2012 and decreased 3.9% compared to July 2013. NYSE Euronext's Tape A matched market share in August 2013 was 30.7%, down from 31.6% in August 2012 but, up from 30.6% in July 2013.
Please click here for the Monthly Transaction Activity Data Table.
|1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.|
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This written communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "hope," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," "could," "future" or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other "forward-looking" information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.
Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE's and NYSE Euronext's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE's and NYSE Euronext's filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext's operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE's, NYSE Euronext's or the combined company's respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management's attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled "Risk Factors" in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE's and NYSE Euronext's respective filings with the SEC that are available on the SEC's web site located at www.sec.gov, including the sections entitled "Risk Factors" in ICE's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and "Risk Factors" in NYSE Euronext's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S−4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus has been delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT CONTAINS IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC's website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE's website at http://www.theice.com and from NYSE Euronext's website at http://www.nyx.com.
Monthly Volume Summary
|Average Daily Volume||Total Volume||Average Daily Volume||Total Volume|
|(Unaudited; contracts in thousands)||Aug-13||Aug-12||% Chg||Aug-13||Aug-12||% Chg||YTD 2013||
% Chg vs.
% Chg vs.
|Number of Trading Days - European Cash||22||23||22||23||170||170|
|Number of Trading Days - European Derivatives||22||23||22||23||171||171|
|Number of Trading Days - U.S. Markets||22||23||22||23||168||168|
|European Derivatives Products||2,841||3,245||-12.5||%||62,495||74,641||-16.3||%||3,970||4.0||%||678,943||2.8||%|
|of which Bclear||408||1,047||-61.0||%||8,983||24,086||-62.7||%||732||-35.3||%||125,113||-36.1||%|
|Total Fixed Income Products||1,746||1,432||21.9||%||38,409||32,933||16.6||%||2,428||35.1||%||415,194||33.5||%|
|Short Term Interest Rate Products||1,552||1,268||22.4||%||34,144||29,164||17.1||%||2,247||36.4||%||384,272||34.8||%|
|Medium and Long Term Interest Rate Products 1||194||164||18.3||%||4,265||3,769||13.2||%||181||20.6||%||30,922||19.2||%|
|Total Equity Products 2||1,001||1,725||-42.0||%||22,016||39,664||-44.5||%||1,451||-25.0||%||248,065||-25.9||%|
|Individual Equity Products||632||1,334||-52.7||%||13,897||30,686||-54.7||%||954||-34.4||%||163,162||-35.1||%|
|Equity Index Products||369||390||-5.5||%||8,119||8,978||-9.6||%||497||3.3||%||84,903||2.1||%|
|of which Bclear||405||1,047||-61.3||%||8,917||24,086||-63.0||%||730||-35.4||%||124,896||-36.2||%|
|Individual Equity Products||352||992||-64.5||%||7,745||22,821||-66.1||%||633||-40.5||%||108,163||-41.2||%|
|Equity Index Products||53||55||-3.1||%||1,172||1,265||-7.3||%||98||43.4||%||16,733||41.7||%|
|U.S. Derivatives Products|
|Equity Options 3|
|NYSE Euronext Options Contracts||3,347||3,088||8.4||%||73,627|